Molecular characterization and susceptibility screening for methicillin-resistant Staphylococcus aureus reveals the dominant clones in a tertiary care hospital in Al Qassim, Saudi Arabia

Kamaleldin B. Said¹, Ahmed N. Aljarbou², Mohamed S. Alorainy³, Elhassan M. A. Saeed⁴,⁵, Khalid M. Hassan⁶

¹Department of Pathology and Microbiology, College of Medicine, University of Hail, Hail, Saudi Arabia, ²Dean, Al Ghad International Colleges for Applied Medical Sciences, Qassim, Saudi Arabia, ³Department of Pharmacy Practice, College of Pharmacy, Qassim University, Buraidah 51452, Saudi Arabia, ⁴Department of Veterinary Medicine, College of Agriculture and Veterinary Medicine, Qassim University, Buraidah, Saudi Arabia, ⁵Department of Microbiology, Faculty of Veterinary Medicine, Khartoum University, Khartoum, Sudan, ⁶Department of Pathology, King Fahad Specialist Hospital, Buraidah 52366, Saudi Arabia

Address for correspondence:
Kamaleldin B. Said, Department of Pathology and Microbiology, College of Medicine, University of Hail, Hail, Saudi Arabia.
Tel.: +966-500771459. E-mail: kamaledin@hotmail.com

ABSTRACT

Objective: Staphylococcus aureus has become an important pathogen in hospitals worldwide. Despite its differentiation into human and animal lineages, common methods are used for genotyping. While these methods are useful, they are based on the stable genome, and hence, are insensitive to host-specific subtyping. The objectives of this study were to investigate the repeat-domain of the Clumping-Factor A gene (clfA-R) as an objective and adaptation-sensitive approach.

Methodology: We have used 113 isolates for susceptibility testing and genotyping by polymerase chain reaction amplification of the clfA-R regions. Of these, 105 were from King Fahad Specialist Hospital, Buraidah and eight were published sequences used as references. Isolates were further confirmed as S. aureus by the commercial Kits. Amplicon sizes were measured and the number of the 18-bp-repeating-units in each isolate was determined against that of methicillin-resistant S. aureus COL (MRSA) sequence.

Results: Results showed that all 42 nasal screening isolates (100%) and all but six isolates from clinical specimens were MRSA with 37% of the former and 50% of the latter isolates showing community-acquired-MRSA susceptibility patterns. clfA-R analysis grouped 113 isolates into 14 repeat-genotypes. The two dominant types, D and X, represented the long- and short clfA-R types found in humans and animals, respectively. Linezolid, rifampicin, and vancomycin were the drugs of choice.

Conclusions: clfA-R was useful in rapid genotyping and implied host-specific phenotypic properties of the ClfA. It has been recommended that the approach used in regional laboratories for uniform strain-profiling. Future work will show more insights into the gene content and origins of clones.

Keywords: Molecular epidemiology, molecular typing, methicillin-resistant Staphylococcus aureus screening, Staphylococcus aureus

Introduction

Despite enormous efforts, Staphylococcus aureus continued to emerge causing outbreaks and posing significant clinical challenges in hospitals worldwide. Of particular concern is the devastating form of septicemia-pyaemia first described by Ogston[1] and still results in high rates of morbidity and mortality.[2] Through centuries, this pathogen has survived huge advances in medical care and adapted to become the leading cause of skin and soft tissue infections today.[3,4] A unique property of S. aureus is the possession of novel and highly advanced mechanisms of adaptation, in a clonal genome, that enables the emergence of host-associated strains.

Although it has been well established that S. aureus has a stable genome based on house-keeping and highly polymorphic genes, new strains continued to emerge in different hosts.[5,6] For instance, several countries in the region reported recent emergences of novel methicillin-resistant S. aureus (MRSA) strains demonstrating an expanding MRSA repertoire. These included the emergence of previously unreported clonal complexes and novel strains.[7,8] Thus, since its appearance in the early 1960s,[9] hospital-associated-MRSA incidence steadily increased accounting for over 60% of the species isolates in US hospitals alone by the year 2004 according to the National Nosocomial Infection Surveillance system data (2004).[10] The annual hospitalization rate of 125,969 was
reported for *S. aureus* with mortality rates similar to that of AIDS, tuberculosis, and viral hepatitis combined.\[^{13,14}\] This was followed by the most alarming incidence in MRSA history, the emergence of community acquired-MRSA (CA-MRSA) lineage as a primary cause of skin, soft tissue, and bloodstream infections in young healthy adults and children with no prior health-care exposure.\[^{15,16}\] Since then, decades of global outbreaks of CA-MRSA lineages, including USA300 and USA400 were reported.\[^{17,18}\] Furthermore, the emergence of human pandemic clones originated in bovine mastitis and other livestock posed significant risks to public health.\[^{19-22}\] We have surveyed Al-Qassim regional hospital and identified many multi-resistant bacterial pathogens. Among them, *S. aureus* was one of the most resistant isolates found with patterns typical of CA-MRSA clones.\[^{23}\]

While significant resources and time were given to basic research on human *S. aureus*, little attention was placed on the development of sensitive and host-specific typing and detection systems. The genome-based typing markers, although useful as gold standards, are often limited by their low discriminatory powers toward newly emerging subtypes in different hosts. This is mainly due to the clonality of *S. aureus* genome from different host species. For example, pathogenic strains from humans and animals showed the same genetic background and gene content.\[^{24,25}\] Similarly, there was no genomic diversity between commensal and pathogenic strains in a comparative genome study.\[^{26}\] Thus, the common genetic background allowed DNA transfer between host-specialized lineages.\[^{27,28}\] Consequently, acquisitions of new factors triggered significant global transcriptome shifts leading to the evolution of CA-MRSA lineages. These were characterized by panton-valentine leucocidin toxin and SCCmec type IV element and susceptibility to non-β-lactam antibiotics.\[^{29-31}\] While the acquisition of elements played a role in virulence, it does not explain the overall enhanced virulence *per se*.\[^{18,32,33}\] For these reasons genome-based molecular typing markers, although useful as gold standards, are often limited by low sensitivity toward new subtypes. Alternatively, intrinsic, constitutive, and universal markers that are strategically located on cell surfaces of bacterial species can be useful candidates in objectively sub-typing host-specific lineages.

It has been well established that the repeat-rich adaptation-sensitive surface proteins play major roles in adaptation. Repeat based markers are often superior to multilocus sequence typing in the detection of polymorphism among *S. aureus* isolates.\[^{34}\] For example, Clumping Factor B (*clfB*) showed congruence with SCCmec and was a promising alternative to pulsed-field gel electrophoresis when used in a double-locus typing with spa, another repeat-based typing system.\[^{35}\] However, *clfB* biological activity is limited only to log phase under increased oxygenation because it is digested by the stationary phase proteases.\[^{36-38}\] In contrast, clumping-factor A (*clfA*) is constitutively expressed under host environments. Moreover, although SCCmec typing has been widely used, its mobility and the appearances of invasive methicillin-sensitive *S. aureus* (MSSA)\[^{39}\] made it less useful than intrinsic typing markers.

The objectives of the present work were to first identify MRSA phenotypes from clinical specimens and screening procedures and to genotype resulting MRSA isolates using the R domain of the *clfA* gene.

**Methodology**

**Ethical statement**

Although this study used only bacterial isolates, and hence, would be exempted from criteria under Human Subject Research, ethical approval for this project was obtained from the Ethical Committee of the Ministry of Health, General Health Affairs Directorate, Training, Medical Education and Research, Al Qassim Province, no. 687/44/45 and No 688/44/45 to fully comply with the request of ethical clearance.

**Bacterial strains, sequences, and susceptibility testing**

A total of 113 MRSA isolates and strains were used in this study for genotyping by R-domain of the *clfA* gene. Eight isolates were published genome sequences of major strains [Table 1], but the majority of isolates (105) were from King Fahad Specialist Hospital (KFSH) [Tables 2a,b and 3], Buraidah, KSA. The KFSH in Buraidah, Al-Qassim Province is a 540-bed tertiary care center that receives patients from all socioeconomic strata within Al-Qassim Province of about 1 million in population size. The 105 isolates used in this study were both from routine nasal MRSA screening procedures using the more stable agent cefoxitin carried out on patient admission as well as from clinical specimens submitted to the microbiology laboratory department for routine diagnosis and antimicrobial susceptibility testing. Isolates were first identified through routine standard bacteriological methods and inoculation of an automated system for rapid identification (ID) and antimicrobial susceptibility testing. The ID and susceptibility testing were done using automated Microscan according to the standard recommendations. This was followed by disc diffusion testing against oxacillin and susceptibility to other non-beta-lactams as possible indicators for CA-MRSA. Interpretations were based on the Clinical and Laboratory Standards Institute (2012)\[^{40}\] guidelines.

Isolates were confirmed as *S. aureus* using a specific detection kit (*S. aureus* Detection Kit 29300 Norgen Biotek, Thorold, ON, Canada). All isolates were from different specimens. Antimicrobial susceptibility testing was carried out according to Said et al., (2014).\[^{23}\] In addition, published sequences of 8 strains (mastitis strains RF122, MRSA252, MRSA COL, MSSA 476, N315, MW2, Mu50, and USA300) were used as references for analysis. Glycerol stocks of isolates in trypticase soy broth (TSB) were stored at −80°C.
Genomic DNA extraction

All isolates were refreshed and grown for 18 h in Luria-Bertani and TSB media. Genomic DNA extractions were carried out according to the manufacturer’s protocol for Bacterial Genomic DNA Isolation (Kit # 17900 Norgen Biotek, Thorold, ON, Canada). For efficient yield, *S. aureus* isolates were pre-digested with lysostaphin (Sigma) and lysozyme (Sigma) to break cell walls and render extraction of nucleic acids easy. Isolated genomic DNA was quantitated and either used immediately after quantitation or stored at −20°C for a short time or at −80°C for long storage period until used.

Polymerase chain reaction (PCR) amplification and electrophoresis

All of the isolates were tested to confirm species identity and the presence of the *clfA* gene with intact repeat regions. Several optimization experiments were carried out to set up template amount, primer locations, gel systems, software, and documentation. In the final round of amplification, high-quality gel resolutions were obtained in PCR products amplified in a series of gels 1–8. The representative Figure 1 shows the indicated gel picture with isolates from 26 to 105 (Lanes 26–105). On this figure, the sizes of amplicons are shown above the DNA bands, and the corresponding repeat copy numbers are shown below the bands.

PCR amplification of *clfA* R-domain typing was carried out as described previously with some modifications.\(^{41,42}\) Briefly, Techne Thermal Cycler PCR #TC-412 was used for amplification of the R-domains from the *clfA* gene of all isolates using specific (desalted) primers pairs as follows: Forward primer, *cf-R* AGGTGAATTAGGCGGAACTAC and Reverse primer, *cf-F* TCCTGAACAACCTGATGAGC and *clfA* AGGTGAATTAGGCGGAACTAC (Invitrogen Life Technologies, Europe). The PCR conditions used were: Initial denaturation at 94°C for 4 min followed by 30 cycles each of denaturation for 1 min at 94°C, annealing at 58°C for 1 min, and extension at 72°C for 1 min, and final extension for 1 min at 72°C. A final hold at 10°C was added, but all samples were removed immediately after finishing. Agarose (Invitrogen Inc) gel electrophoresis of PCR amplicons was carried out in a Bio-Rad Sub-Cell for submerged horizontal electrophoresis (15 cm × 25 cm; 15-well combs) and in 1 litter base buffer volumes in the tanks connected to Bio-Rad PowerPac 200 electrophoresis power supply. After electrophoresis, ethidium bromides (Invitrogen Inc.) stained gels were illuminated and gel pictures were analyzed in the gel photo-doc system using the associated software.

*clfA*-R domain-based genotyping

PCR amplicons sizes on gels were measured against the 100 bp markers (Invitrogen Inc). The amplicon sizes were shown (bp) on the gel band, and its estimated corresponding copy number was indicated below the band. Because primers flanked a stable location on *S. aureus* genome sequence, differences in product sizes were expressed as differences in R-domain copy numbers

---

**Table 1:** Numbers, names, addresses, and sources of isolates and sequenced strains used in the *clfA*-R-domain based genotyping of Methicillin resistant *Staphylococcus aureus*

| No. | Strain/isolate | Source                      | Site                                   | Origin         | *clfA* repeat copy number and genotype |
|-----|----------------|-----------------------------|------------|---------------|---------------------------------------|
| 105 | Methicillin resistant *Staphylococcus aureus* isolate | TIGR (J. Craig Venter Institute) | King Fahad Specialist Hospital, Buraidah | Human         | Table 3                                |
| 1   | *S. aureus* subsp. aureus COL (MRSA)                  | TIGR (J. Craig Venter Institute) | http://www.tigr.org                    | Human         | 50.5=genotype C                        |
| 2   | *S. aureus* subsp. aureus MRSA252 (HA-MRSA)          | Welcome Trust Sanger Institute | http://www.sanger.ac.uk/               | Human         | 66=genotype A                          |
| 3   | *S. aureus* subsp. aureus N315 HA-MRSA               | Juntendo University           | http://www.staphylococcus.org/jp/      | Human         | 59.5=genotype A                        |
| 4   | *S. aureus* subsp. aureus MSSA476 (CA-MSSA) hypervirulent | Welcome Trust Sanger Institute | http://www.sanger.ac.uk/               | Human         | 49=genotype C                          |
| 5   | *S. aureus* subsp. aureus MW2 (CA-MRSA)              | NITE                         | http://www.bio.nite.go.jp/             | Human         | 51=genotype C                          |
| 6   | *S. aureus* subsp. aureus Mu50 MRSA–VRSA            | Juntendo University           | http://www.staphylococcus.org/jp/      | Human         | 49.5=genotype C                        |
| 7   | *S. aureus* subsp. aureus USA300 strong association with unusually invasive disease (invasive MRSA) | University of California, San Francisco | http://www.ncbi.nlm.nih.gov/sites/entrez?db=genomeprj&md=Retrieve&dopt=Overview&list_uids=16313 | Human         | 49=genotype C                        |
| 8   | Mastitis *S. aureus* RF122                           | University of Minnesota      | http://www.ncbi.nlm.nih.gov/sites/entrez?db=genomeprj&md=Retrieve&dopt=Overview&list_uids=63 | Bovine        | 46=genotype Q                         |

**MRSA:** Methicillin-resistant *S. aureus*, **MSSA:** Methicillin-sensitive *S. aureus*, **S. aureus:** *Staphylococcus aureus*
Table 2a: Antimicrobial susceptibility test, amplified *clfA* R-domain sizes, the corresponding repeat copy numbers and associated genotypes of methicillin-resistant *S. aureus* isolated from MRSA screens and clinical specimens at King Fahad Specialist Hospital, Buraidah

| Gel Isolate No. | Specimen site | Cefoxitin nasal screening | Clindamycin | Ciprofloxacin | Erythromycin | Gentamicin | Linezolid | Oxacillin Pen blac | Rifampin | Tetracyclin | Trim/ SUL | Vancomycin | MRSA/ MSSA | MRSA/ MSSA genotype (RT) | clfA-Repeat copy number | Total clfA-Repeat domain size |
|----------------|--------------|--------------------------|-------------|--------------|-------------|------------|----------|------------------|---------|-------------|---------|-----------|-----------|--------------------------|---------------------------|-----------------------------|
| 1              | Wound        | Positive                 | S           | S            | S           |            | S        | Positive         | S       | S           | S       | S         | MRSA      | X                       | 52                        | 1000                        |
| 2              | Wound        | Positive                 | S           | S            | S           |            | S        | Positive         | S       | S           | S       | S         | MRSA      | Q                       | 45                        | 850                         |
| 3              | Wound        | Positive                 | R           | R            | R           |            | S        | Positive         | S       | R           | R       | S         | MRSA      | X                       | 52                        | 1000                        |
| 4              | Wound        | Positive                 | S           | S            | S           |            | S        | Positive         | S       | S           | S       | S         | MRSA      | X                       | 52                        | 1000                        |
| 6              | Wound        | Positive                 | R           | R            | R           |            | S        | Positive         | S       | R           | R       | S         | MRSA      | A                       | 65                        | 1250                        |
| 8              | Wound        | Positive                 | R           | S            | R           |            | S        | Positive         | S       | R           | S       | S         | MRSA      | X                       | 52                        | 1000                        |
| 9              | Wound        | Positive                 | S           | S            | S           |            | R        | Positive         | S       | R           | R       | S         | MRSA      | X                       | 52                        | 1000                        |
| 10             | Wound        | Positive                 | S           | S            | S           |            | R        | Positive         | S       | S           | S       | S         | MRSA      | E                       | 55                        | 1050                        |
| 11             | Tech ASP     | Positive                 | R           | S            | R           |            | S        | Positive         | S       | R           | S       | S         | MRSA      | X                       | 52                        | 1000                        |
| 12             | Wound        | Positive                 | R           | R            | R           |            | S        | Positive         | S       | R           | R       | S         | MRSA      | B                       | 60                        | 1150                        |
| 13             | Ear          | Positive                 | S           | S            | S           |            | S        | Positive         | S       | S           | S       | S         | MRSA      | B                       | 60                        | 1150                        |
| 14             | Wound        | Positive                 | S           | R            | S           |            | R        | Positive         | S       | S           | S       | S         | MRSA      | D                       | 57                        | 1100                        |
| 15             | Wound        | Positive                 | R           | R            | R           |            | R        | Positive         | S       | R           | R       | S         | MRSA      | X                       | 52                        | 1000                        |
| 16             | Wound        | Positive                 | R           | R            | R           |            | S        | Positive         | S       | R           | R       | S         | MRSA      | X                       | 52                        | 1000                        |
| 17             | Wound        | Positive                 | R           | S            | R           |            | S        | Positive         | S       | R           | R       | S         | MRSA      | X                       | 52                        | 1000                        |
| 18             | Wound        | Positive                 | R           | R            | R           |            | S        | Positive         | S       | R           | R       | S         | MRSA      | X                       | 52                        | 1000                        |
| 23             | Tech ASP     | Positive                 | S           | S            | S           |            | S        | Positive         | S       | S           | S       | S         | MRSA      | Q                       | 47*                       | 900                         |
| 24             | Blood        | Positive                 | R           | R            | R           |            | R        | Positive         | S       | R           | NA      | S         | MRSA      | Q                       | 47*                       | 900                         |
| 25             | Wound        | Positive                 | R           | R            | R           |            | R        | Positive         | S       | R           | NA      | S         | MRSA      | Q                       | 47*                       | 900                         |
| 26             | Wound        | Positive                 | R           | R            | R           |            | S        | Positive         | S       | R           | NA      | S         | MRSA      | E                       | 55                        | 1050                        |
| 27             | Blood        | Positive                 | R           | R            | R           |            | S        | Positive         | R       | S           | R       | S         | MRSA      | D                       | 57                        | 1100                        |
| 28             | Wound        | Positive                 | S           | S            | S           |            | S        | Positive         | S       | R           | NA      | S         | MRSA      | E                       | 55                        | 1050                        |
| 29             | Wound        | Positive                 | S           | S            | S           |            | S        | Positive         | S       | R           | S       | S         | MRSA      | D                       | 57                        | 1100                        |
| 30             | Wound        | Positive                 | R           | R            | R           |            | R        | Positive         | S       | R           | R       | S         | MRSA      | E                       | 55                        | 1050                        |
| 31             | Wound        | Positive                 | S           | S            | S           |            | S        | Positive         | S       | S           | S       | S         | MRSA      | D                       | 57                        | 1100                        |
| 32             | Wound        | Positive                 | S           | S            | S           |            | S        | Positive         | S       | S           | S       | S         | MRSA      | F                       | 49                        | 950                         |
| 33             | Wound        | Positive                 | R           | S            | R           |            | S        | Positive         | S       | S           | S       | S         | MRSA      | F                       | 49                        | 950                         |
| 34             | Tech ASP     | Positive                 | R           | S            | R           |            | S        | Positive         | R       | R           | S       | S         | MRSA      | E                       | 55                        | 1050                        |
| 35             | Tech ASP     | Positive                 | R           | R            | R           |            | S        | Positive         | R       | R           | R       | S         | MRSA      | E                       | 55                        | 1050                        |
| 36             | Wound        | Positive                 | S           | S            | S           |            | S        | Positive         | S       | R           | S       | S         | MRSA      | E                       | 55                        | 1050                        |
| 37             | Wound        | Positive                 | S           | S            | S           |            | S        | Positive         | S       | R           | S       | S         | MRSA      | D                       | 57                        | 1100                        |
| 40             | Wound        | Positive                 | R           | R            | R           |            | S        | Positive         | S       | R           | S       | S         | MRSA      | E                       | 55                        | 1050                        |
| 41             | Wound        | Negative                 | S           | S            | S           |            | S        | Positive         | S       | S           | S       | S         | MSSA      | B                       | 60                        | 1150                        |
Said, et al.: MRSA screening by clfA reveals dominant clones

Table 2a: (Continued)

| Gel | Isolate No. | Specimen site | Cefoxitin nasal screening | Clindamycin | Ciprofloxacin | Erythromycin | Gentamycin | Linezolid | Oxacillin Pen blac | Rifampin | Tetracycline | Trim/ SUL | Vancomycin | MRSA/ MSSA | clfA-Repeat genotype (RT) | clfA-Repeat copy number | Total clfA-R-domain size |
|-----|-------------|---------------|---------------------------|-------------|---------------|--------------|-------------|-----------|------------------|----------|-------------|----------|------------|----------|--------------------------|--------------------------|-------------------------|
| 42  | Wound       | Positive      | S                         | S           | S             | S            | S           | R         | Positive         | S        | S           | S        | MRSA       | X        | 52           | 1000                    |                      |
| 43  | Wound       | Positive      | R                         | R           | R             | R            | S           | R         | Positive         | S        | R           | R        | MRSA       | B       | 60           | 1150                    |                      |
| 44  | Wound       | Positive      | S                         | S           | S             | S            | S           | R         | Positive         | S        | S           | S        | MRSA       | D       | 57           | 1100                    |                      |
| 45  | Blood       | Positive      | S                         | S           | S             | S            | S           | R         | Positive         | S        | S           | S        | MRSA       | X       | 52           | 1000                    |                      |
| 46  | Ear         | Negative      | R                         | S           | S             | R            | S           | S         | Positive         | S        | S           | S        | MSSA       | D       | 57           | 1100                    |                      |
| 47  | Ear         | Negative      | S                         | S           | S             | S            | S           | S         | Positive         | S        | R           | S        | MSSA       | D       | 57           | 1100                    |                      |
| 48  | Ear         | Negative      | S                         | S           | S             | S            | S           | S         | Positive         | S        | S           | S        | MSSA       | X       | 52           | 1000                    |                      |
| *   |             |               |                           |             |               |              |             |           |                  |          |             |          |            |          |                          |                          |                        |
| 50  | Trch ASP    | Positive      | S                         | R           | S             | R            | S           | R         | Positive         | S        | R           | S        | MRSA       | D       | 57           | 1100                    |                      |
| 51  | Ear         | Negative      | S                         | S           | S             | S            | S           | S         | Positive         | S        | R           | S        | MSSA       | Q       | 45*          | 850                     |                      |
| 52  | Wound       | Positive      | R                         | S           | R             | S            | S           | R         | Positive         | S        | R           | S        | MRSA       | X       | 52           | 1000                    |                      |
| 53  | Wound       | Positive      | S                         | S           | S             | S            | R           | S         | Positive         | S        | R           | S        | MSSA       | Q       | 45*          | 850                     |                      |
| *   |             |               |                           |             |               |              |             |           |                  |          |             |          |            |          |                          |                          |                        |
| 56  | Wound       | Positive      | R                         | R           | R             | R            | S           | R         | Positive         | S        | R           | R        | MRSA       | X       | 52           | 1000                    |                      |
| 57  | Wound       | Positive      | R                         | R           | R             | R            | S           | R         | Positive         | S        | R           | R        | MRSA       | X       | 52           | 1000                    |                      |
| 58  | Trch ASP    | Negative      | S                         | S           | S             | S            | S           | S         | Positive         | S        | S           | S        | MSSA       | F       | 49           | 950                     |                      |
| 59  | Blood       | Positive      | R                         | R           | R             | R            | S           | R         | Positive         | R        | R           | R        | MRSA       | F       | 49           | 950                     |                      |
| 60  | Wound       | Positive      | R                         | R           | R             | R            | S           | R         | Positive         | S        | R           | R        | MRSA       | B       | 60           | 1150                    |                      |
| 61  | Wound       | Positive      | R                         | R           | R             | R            | S           | R         | Positive         | S        | R           | R        | MRSA       | G       | 21           | 400                     |                      |
| 62  | Wound       | Positive      | R                         | S           | R             | S            | S           | R         | Positive         | S        | S           | S        | MRSA       | D       | 57           | 1100                    |                      |
| 63  | Screening   | Positive      | R                         | R           | R             | R            | R           | S         | Positive         | S        | R           | R        | MRSA       | B       | 60           | 1150                    |                      |

‡(X=52, C=50±1, Q=45±1) *Isolates missed; +Isolates re-run on a different lane on the gels. Bolded antibiotics=drugs of choice. MRSA: Methicillin-resistant S. aureus, MSSA: Methicillin sensitive S. aureus, S. aureus: Staphylococcus aureus, clfA: Clumping-Factor A.
Table 2b: Antimicrobial susceptibility test, amplified cflA R-domain sizes, the corresponding copy numbers and associated genotypes of methicillin-resistant *Staphylococcus aureus* recovered from MRSA screening at King Fahad Specialist Hospital, Buraidah

| Gel | Isolate no | Specimen site | Cefoxitin sensitive | Ciprofloxacin | Erythromycin | Gentamicin | Linezolid | Oxacillin Pen blac | Rifampin | Tetrazycline | Trim/sul | Vancomycin | MRSA/ MSSA |clfA-Repeat genotype (RT) | clfA-Repeat copy number | Total clfA-R-domain size (bp) |
|-----|------------|---------------|---------------------|---------------|--------------|------------|----------|-------------|----------|-------------|---------|------------|-----------|--------------------------|-----------------------------|---------------------------|
| 6   | 64 Screen positive | R | R | R | S | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 65 | Screen positive | R | R | R | S | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 66 | Screening positive | S | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 67 | Screening positive | S | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 68 | Screening positive | S | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 70 | Screening positive | S | S | S | R | S | S | S | S | S | S | S | S | S | S | MRSA X | 52 | 1000 |
| 71 | Screening positive | S | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 72 | Screening positive | S | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 73 | Screening positive | R | R | R | S | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 74 | Screening positive | R | R | R | S | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 75 | Screening positive | S | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 77 | Screening positive | R | S | R | S | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 78 | Screening positive | S | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 79 | Screening positive | R | S | R | S | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 80 | Screening positive | R | S | R | R | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 81 | Screening positive | R | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 82 | Screening positive | R | S | R | R | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 83 | Screening positive | S | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 84 | Screening positive | R | S | R | R | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 85 | Screening positive | R | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA J | 42 | 800 |
| 86 | Screening positive | R | S | R | R | S | S | S | S | S | S | S | S | S | S | MRSA Q | 47* | 900 |
| 87 | Screening positive | R | S | R | R | S | S | S | S | S | S | S | S | S | S | MRSA X | 52 | 1000 |
| 88 | Screening positive | S | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 89 | Screening positive | R | R | R | R | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
| 90 | Screening positive | S | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA X | 52 | 1000 |
| 91 | Screening positive | S | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA X | 52 | 1000 |
| 92 | Screening positive | R | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA X | 52 | 1000 |
| 93 | Screening positive | R | S | R | R | S | S | S | S | S | S | S | S | S | S | MRSA K | 53 | 1020 |
| 94 | Screening positive | R | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA K | 53 | 1020 |
| 95 | Screening positive | S | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA F | 49 | 950 |
| 96 | Screening positive | R | R | R | R | S | S | S | S | S | S | S | S | S | S | MRSA C | 51 | 980 |
| 97 | Screening positive | S | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA Q | 47* | 900 |
| 98 | Screening positive | R | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA K | 53 | 1020 |
| 99 | Screening positive | R | R | R | R | S | S | S | S | S | S | S | S | S | S | MRSA C | 51 | 980 |
| 100 | Screening positive | S | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA L | 23 | 450 |
| 101 | Screening positive | S | S | S | R | S | S | S | S | S | S | S | S | S | S | MRSA B | 60 | 1150 |
| 102 | Screening positive | S | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA E | 55 | 1050 |
| 103 | Screening positive | S | S | S | R | S | S | S | S | S | S | S | S | S | S | MRSA B | 60 | 1150 |
| 104 | Screening positive | S | S | S | R | S | S | S | S | S | S | S | S | S | S | MRSA B | 60 | 1150 |
| 105 | Screening positive | S | S | S | S | S | S | S | S | S | S | S | S | S | S | MRSA D | 57 | 1100 |
Said, et al.: MRSA screening by clfA reveals dominant clones

Table 3: Number and dominant clfA genotypes of methicillin Staphylococcus aureus isolated from MRSA screening and clinical specimens at King Fahad Specialist Hospital, Buraidah, KSA

| No of clfA-types | Repeat Type (RT)* (X=52, C=50, Q=45±1) | Number of isolates in each genotype | Index of discrimination |
|------------------|----------------------------------------|-------------------------------------|------------------------|
| 14 Genotypes A-L and Q to X | D | 24 | 0.9 |
|                  | X | 19 |
|                  | B | 13 |
|                  | E | 11 |
|                  | Q | 8 |
|                  | F | 8 |
|                  | K | 4 |
|                  | C | 2 |
|                  | H | 1 |
|                  | I | 1 |
|                  | J | 1 |
|                  | L | 1 |
|                  | A | 1 |
|                  | G | 1 |

clfA: Clumping-factor A

Discriminatory power of clfA typing

Discriminatory power of clfA typing was carried out by determination of RTs based on differences in the copy number of the 18-bp tandem repeats within the R domain of the clfA gene. The online discriminatory power calculator (http://biophp.org/stats/discriminatory_power/demo.php) was used to calculate the index of discrimination (ID) of isolates [Table 2], where a value of one indicated that each isolate was different and a value of 0 indicated that all isolates were identical. The numerical index of discriminatory power was used to give numerical estimates for strain typing, and the values (defined as the average probability that the typing system will assign a different type to two unrelated strains randomly sampled in the microbial population of a given taxon) were estimated, as described previously.[43] We attempted to correlate relationships based on the combined genetic as well as biological differences, i.e., the repeat unit differences as a measure of protein polymorphism among isolates under different host conditions. This would allow a rapid and specific primary screening tool without the need for extensive sequencing.

Results

As shown in Table 3, all MRSA isolates identified in clinical specimens, except for six mostly from the ear, were also MRSA positive for nasal screening. The aforementioned six MSSA isolates were penicillin resistant but susceptible to semisynthetic penicillinase-stable penicillins, i.e., oxacillin and also to cefoxitin nasal screening and non-beta-lactam antibiotics. Table 2a also shows significant number of MRSA isolates (37%) susceptible to other non-beta-lactams. In addition, the nasal screening procedure of 42 patients [Table 2b] revealed similar susceptibility pattern to that in Table 2a. These were 100% positive for MRSA, oxacillin, and penicillin with 50% showing the CA-MRSA susceptibility pattern. Antimicrobial susceptibility testing showed that linezolid, rifampicin, and vancomycin were still among the drugs of choice for the treatment of staphylococcal infections in the hospital.

clfA typing: clfA-genotyping identified 14 RTs designated, A to L, and Q and X with a high discriminatory power of ID = 0.9 [Table 2]. The eight published strains [Table 1] belonged to three RTs, namely, A, C, and Q. The majority of the isolates belonged to the first six RTs. Based on the length of the R domain, two major clonal groups were identified, namely, (a) long clfA-R group included A and I with 65 and 63 copy numbers, respectively, that were represented by single isolates each. These were followed by types B (13 isolates and 60 copies), and D which were the major clone in this group with 24 isolates (22%) and had 57 repeat copies. The source of isolates in the long R domain groups were almost always from wound infections and nasal MRSA screening.

The second clonal group was the (b) short clfA-R group represented mainly by the type X which was the major clone...
Figure 1: Representative gel pictures of polymerase chain reaction amplicons of the Clumping-Factor A-R domains from methicillin-resistant Staphylococcus aureus isolates (Lanes 26-51) recovered from screening and clinical specimens in King Fahad Specialist Hospital, Buraidah, Saudi Arabia. (Ethidium bromide illuminated, 1% agarose (Invitrogen Inc) gel picture in Bio-Rad Sub-Cell (15 cm × 25 cm; 15-well combs) tank for submerge electrophoreses in 1-litter base buffer volumes using Bio-Rad PowerPac 200 electrophoresis power supply)
in this group with 19 isolates (18%) each with 52 copies. The remaining RTs were quite variable and were usually represented by a few isolates. These were RT E (11 isolates, 10%), F and Q (8 isolates each, 7.6%), and K and C with 4 and 2 isolates, respectively. All other types had a single isolate each. This study also identified a few rare types with unusually smaller clfA-R domains and much lower copy numbers than those of bovine lineages. These included genotypes G, H, J, and L with only 21, 31, 42, and 23 copies of repeats, respectively.

**Discussion**

This study investigated the usefulness of a PCR based genotyping and clonal differentiations of MRSA isolate using the repeat domain of the clfA gene as a marker. The finding that all isolates of nasal screening as well as clinical specimens [Table 2a and b], except for six, were MRSA positive correlates well with potential endogenous infections and MRSA carriage state. This agrees with the previous report that MRSA nares’ swab was a more accurate predictor of MRSA wound infection compared with clinical risk factors in emergency department patients with skin and soft tissue infections.[45] However, the pattern similarity of the aforementioned six ears MSSA isolates to that of common CA-MRSA phenotypes, i.e., resistance to penicillin and susceptibility to non-beta-lactam antibiotics, strongly imply potential evolutionary dynamics of two lineages with two different mechanisms of invasiveness. This also indicates to the need for reducing the strong bias for sequencing only epidemic MRSA over MSSA strains. This practice has obscured the evolutionary lines of highly specialized MSSA populations.[44] Furthermore, in this study, significant rates of MRSA isolates from clinical specimens (37%) and screening (50%) showed the widely reported pattern of the CA-MRSA lineage [Table 2a and b].

The clfA-Repeat typing identified two major clonal groups based on their clfA-R domain lengths. These were named as “long clfA-R group” that included RTs A, I, B, and D. The latter was the major clone in this group with 24 isolates. The fact that this group was almost always recovered from nasal MRSA screening and wound infections implied their association with the host. These findings are consistent with the earlier reports where 21 of the 24 isolates from wound infections had the longest clfA-R domain.[41] It has been shown that variations in coding tandem repeat results in length polymorphism and in turn affect the function or antigenicity of the protein at that specific host.[45] The obtained phenotypic property of the marker is significant in the mechanisms of adaptation and colonization of a specific host site. In turn, exploitation of this structural property can be useful in host- and organ-specific typing for tracing the sources of infection.

The second clonal group was the “short clfA-R domain group” represented mainly by type X (19 isolates with 52 copies each) as the major clone in this group. The length of the clfA-R region in all these isolates was typical of those isolated from the bovine mastitis lineage of *S. aureus*[41,42] implying potential transmissions from the animal. Cross transmissions to humans through dairy and other animal products have been commonly reported in different geographic regions around the globe. This is further supported by the high prevalence rates of short RT (X and Q) only in clinical specimens from infections in contrast to those from the resident nasal carriage (long RTs D and B) recovered mainly from nares’ screening. Using clfA-R domain typing, we have previously established that the existence of long and variable repeats in humans and the dominance of a clonal motif in bovine mastitis implied the occurrence of a specific selection in the bovine mammary gland. For these reasons, vigilance is needed for monitoring staphylococcal populations at the human-animal interface where major typing methods lack discriminatory power for host-specific differences.[46]

**Conclusions**

In this study, we have investigated the usefulness of the R domain of the clfA core adhesion gene in the rapid ID of MRSA clones and their host- and organ-specific phenotypic profiles of the marker. The majority of isolates fell into two dominant repeat-types, D and X that represented the long- and short clfA-R types found in humans and animals, respectively. Thus, clfA-R domain was useful in the differentiation of MRSA clones and implied phenotypic host-specificity inherent in the marker. It has also been recommended that clfA-R screening be a unified method in regional laboratories for quick ID and tracking of circulating clones. Future vertical genetic analysis will show more insights into the gene content and origins of clones.

**Acknowledgment**

This work was supported by a research grant to Dr. Kamaleldin B Said (No. 1378) from the Deanship of Scientific Research, Qassim University.

**Conflicts of Interest**

The authors declare that they all have seen the final submitted draft and that there are no conflicts of interest.

**Ethical Statement**

This study only analyzed bacterial isolates stored after isolation from patients. Any detail about the patient name or privacy was not available to us because we did not work with the patients directly, and hence, would be exempted from criteria under human subject research, ethical approval.

**References**

1. Ogston A. Micrococcus Poisoning. J Anat Physiol 1882;17:24-58.
2. Hassoun A, Linden PK, Friedman B. Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment. Crit Care 2017;21:211.
with potential risk to public health. J Infect Dis 2008;197:205-13.

22. Spoer LE, McAdam PR, Weinert LA, Rambaut A, Hasman H. Livestock origin for a human pandemic clone of community-associated methicillin-resistant Staphylococcus aureus. MBio 2013;4(1).

23. Said KB, Al Jarbou AN, Alraouji M, Eibid H. Surveillance of antimicrobial resistance among clinical isolates recovered from a tertiary care hospital in Al Qassim, Saudi Arabia. Int J Health Sci 2014;8:3-12.

24. van Leeuwen WB, Melles DC, Alaidan A, Al-Ahdal M, Boelens HA, Snijders SV, et al. Host and tissue-specific pathogenic traits of Staphylococcus aureus. J Bacteriol 2005;187:4584-91.

25. Lindsay JA, Moore CE, Day NP, Peacock SJ, Witney AA, Stabler RA, et al. Microarrays reveal that each of the ten dominant lineages of Staphylococcus aureus has a unique combination of surface-associated and regulatory genes. J Bacteriol 2006;188:669-76.

26. Feng Y, Chen CJ, Su LH, Hu S, Yu J, Chiu CH. Evolution and pathogenesis of Staphylococcus aureus: Lessons learned from genotyping and comparative genomics. FEMS Microbiol Rev 2008;32:23-37.

27. Sung, JM, Lindsay, JA. Staphylococcus aureus strains that are hypersusceptible to resistance gene transfer from enterococci. Antimicrob Agents Chemother 2007;51:2189-91.

28. Brody T, Yavatkar AS, Lin Y, Ross J, Kuzin A, Kundu M, et al. Horizontal gene transfers link a human MRSA pathogen to contagious bovine mastitis bacteria. PLoS One 2008;3:e3074.

29. Diep BA, Perdreau-Remington F, Sensabaugh GF. Clonal characterization of Staphylococcus aureus by multilocus restriction fragment typing, a rapid screening approach for molecular epidemiology. J Clin Microbiol 2003;41:4559-64.

30. Robinson DA, Kearns AM, Holmes A, Morrison D, Grundmann H, Edwards G, et al. Re-emergence of early pandemic Staphylococcus aureus as a community-acquired methicillin-resistant clone. Lancet 2005;365:1256-8.

31. Diep BA, Carleton HA, Chang RF, Sensabaugh GF, Perdreau-Remington F. Roles of 34 virulence genes in the evolution of hospital and community-associated strains of methicillin-resistant Staphylococcus aureus. J Infect Dis 2006;193:1495-503.

32. Highlander SK, Hultén KG, Qin X, Jiang H, Yerrarapragada S, Mason EO Jr., et al. Subtle genetic changes enhance virulence of methicillin resistant and sensitive Staphylococcus aureus. BMC Microbiol 2007;7:99.

33. Sung, JM, Lloyd, DH, Lindsay, JA. Staphylococcus aureus host specificity: Comparative genomics of human versus animal isolates by multi-strain microarray. Microbiology 2008;154:1949-59.

34. Baic-Hammer N, Vogel V, Basset P, Blanc DS. Impact of recombination on genetic variability within Staphylococcus aureus clonal complexes. Infect Genet Evol 2010;10:1117-23.

35. Huang CC, Ho CM, Chen HC, Li CY, Tien N, Fan HM, et al. Evaluation of double locus (clfB and spa) sequence typing for studying molecular epidemiology of methicillin-resistant Staphylococcus aureus in Taiwan. J Microbiol Immunol Infect 2017;50:604-12.

36. Said et al., MRSA screening by clfA reveals dominant clones.
39. Marimuthu K, Eisenring MC, Harbarth S, Troillet N. Epidemiology of *Staphylococcus aureus* surgical site infections. Surg Infect (Larchmt) 2016;17:229-35.

40. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Twenty Second Information Supplement 2012 CLSI Document M100-S22; (ISBN1-56238785-5)950. Wayne, PA, USA: Clinical Laboratory Standards Institute; 1987.

41. Said KB, Zhu G, Zhao X. Organ and host-specific clonal groups of *Staphylococcus aureus* from human infections and bovine mastitis revealed by the clumping factor a gene. Foodborne Pathog Dis 2010a;7:111-9.

42. Said KB, Ismail J, Campbell J, Mulvey MR, Bourgault AM, Messier S, *et al*. Regional profiling for determination of genotype diversity of mastitis-specific *Staphylococcus aureus* lineage in Canada by use of clumping factor a, pulsed-field gel electrophoresis, and spa typing. J Clin Microbiol 2010b;48:375-86.

43. Hunter P. Reproducibility and indices of discriminatory power of microbial typing methods. J Clin Microbiol 1990;28:1903-5.

44. Planet PJ, Narechania A, Chen L, Mathema B, Boundy S, Archer G, *et al*. Architecture of a species: Phylogenomics of *Staphylococcus aureus*. Trends Microbiol 2017;25:153-66.

45. Jordan P, Snyder LA, Saunders NJ. Diversity in coding tandem repeats in related *Neisseria* spp. BMC Microbiol 2003;3:23.

46. Schmidt T, Kock MM, Ehlers MM. Molecular characterization of *Staphylococcus aureus* isolated from bovine mastitis and close human contacts in South African dairy herds: Genetic diversity and inter-species host transmission. Front Microbiol 2017;8:511.